salesforce(CRM) - 2026 Q4 - Annual Results
2026-02-25 21:03
Exhibit 99.1 Salesforce Delivers Record Fourth Quarter Fiscal 2026 Results RPO Exceeds $72B, Up 14% Y/Y; $15B OCF Scaling The Agentic Enterprise With 2.4B Agentic Work Units Delivered & 19T Tokens Processed All- Time CEOs of SharkNinja, Wyndham Hotels & Resorts and SaaStr to join Salesforce Earnings Show SAN FRANCISCO, Calif. - February 25, 2026 - Salesforce (NYSE: CRM), the world's #1 AI CRM, today announced results for its fourth quarter and full fiscal year ended January 31, 2026. Financial Highlights "W ...
MYR(MYRG) - 2025 Q4 - Annual Results
2026-02-25 21:03
Exhibit 99.1 MYR Group Inc. Announces Fourth-Quarter and Full Year 2025 Results Thornton, Colo., February 25, 2026 – MYR Group Inc. ("MYR" or the "Company") (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United States and Canada, announced today its fourth-quarter and full year 2025 financial results. Fourth Quarter 2025 Highlights Full Year 2025 Highlights Management Comments Rick Swartz, ...
Ally(ALLY) - 2025 Q4 - Annual Report
2026-02-25 21:02
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Delaware 38-0572512 ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tra ...
Xencor(XNCR) - 2025 Q4 - Annual Report
2026-02-25 21:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________________ FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ____________________________________________ ...
MiMedx(MDXG) - 2025 Q4 - Annual Results
2026-02-25 21:02
MARIETTA, Ga., February 25, 2026 -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "MIMEDX delivered a record year of revenue and profitability in 2025, with fourth quarter results that included net sales growth of 27% year- over-year, net income of $15 million, an Adjusted EBITDA margin of 25% of net sales, and robust free cash flow. These r ...
PolyPid(PYPD) - 2025 Q4 - Annual Report
2026-02-25 21:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission ...
Celldex Therapeutics(CLDX) - 2025 Q4 - Annual Results
2026-02-25 21:01
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. "The enthusiasm for barzolvolimab continues to build, driven by unparalleled efficacy data across multiple indications," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Thi ...
ARKO (ARKO) - 2025 Q4 - Annual Report
2026-02-25 21:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR For the transition period from to . Commission file number 001-39828 ARKO Corp. (Exact Name of Registrant as Specified in Its Charter) ______________________________________________ (State or Other Jurisdiction of Incorporation or Organization) 8565 Magellan Parkway Suite 400 ☐ TRANSITI ...
McGrath Rentp(MGRC) - 2025 Q4 - Annual Report
2026-02-25 21:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) Registrant's telephone number: (925) 606-9200 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-13292 McGRATH RENTCORP (Exact name of registrant as specified in its Charter) (State or other ...
Spok(SPOK) - 2025 Q4 - Annual Results
2026-02-25 21:01
NEWS RELEASE Exhibit 99.1 CONTACT: Al Galgano 952-224-6096 Spok Reports Fourth Quarter And Full Year 2025 Results Q4 Software Operations Bookings Up 14% from Prior Year, and Nearly 83% From the Prior Quarter Year-Over-Year Managed Services Revenue Growth Drives Nearly 5% Growth in Software Revenue Company Provides 2026 Financial Guidance Plano, Tx. (February 25, 2026) - Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced results for the fourth quarter and full y ...